Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

被引：8

作者：

Wainberg, Zev A.

Shitara, Kohei

Van Cutsem, Eric

Wyrwicz, Lucjan

Lee, Keun Wook

Kudaba, Iveta

Garrido, Marcelo

Chung, Hyun Cheol Cheol

Lee, Jeeyun

Castro-Salguero, Hugo Raul

Mansoor, Wasat

Braghiroli, Maria Ignez

Karaseva, Nina

Goekkurt, Eray

Satake, Hironaga

Chao, Joseph

Kher, Uma

Shah, Sukrut

Bhagia, Pooja

Tabernero, Josep

机构：

[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90025 USA

[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[3] Univ Hosp Gasthuisberg, Leuven, Belgium

[4] Katholieke Univ Leuven, Leuven, Belgium

[5] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland

[6] Inst Oncol, Warsaw, Poland

[7] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea

[8] Latvian Oncol Ctr Rakus Gailezers, Riga, Latvia

[9] Pontificia Univ Catolica Chile, Santiago, Chile

[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea

[11] Samsung Med Ctr, Seoul, South Korea

[12] Los Angeles Med Grp, Guatemala City, Guatemala

[13] Christie Hosp NHS Trust, Manchester, Lancs, England

[14] Univ Sao Paolo, Inst Canc Sao Paolo, Sao Paulo, Brazil

[15] SPb SBHI Clin Oncol Dispensary, St Petersburg, Russia

[16] Hematol Oncol Practice Eppendorf, Hamburg, Germany

[17] Univ Canc Ctr Hamburg, Hamburg, Germany

[18] Gen Hosp, Kobe City Med Ctr, Kobe, Hyogo, Japan

[19] City Hope Comprehens Canc Ctr, Duarte, CA USA

[20] Merck & Co Inc, Kenilworth, NJ USA

[21] Hebron Univ Hosp HUVH, Barcelona, Spain

[22] UVic UCC, IOB Quiron, Inst Oncol VHIO, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期

关键词：

D O I：

10.1200/JCO.2022.40.4_suppl.243

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

243

引用

页数：3

共 50 条

[21] Efficacy and side effects of pembrolizumab plus chemotherapy vs. chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A meta-analysis
Li, Jinquan
Hu, Xiaosheng
Zhang, Shanzhong
[J]. ONCOLOGY LETTERS, 2024, 28 (02)
[22] Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis
Liu, Bo-Wei
Shang, Qi-Xing
Yang, Yu-Shang
Chen, Long-Qi
[J]. FRONTIERS IN ONCOLOGY, 2023, 13
[23] Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1-positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial.
Chung, Hyun Cheol
Kang, Yoon-Koo
Chen, Zhendong
Bai, Yuxian
Ishak, Wan Zamaniah Wan
Shim, Byoung Yong
Park, Youngiee
Koo, Dong-Hoe
Lu, Jin Wei
Xu, Jianming
Bhagia, Pooja
Kuang, Shu
Shih, Chie-Schin
Qin, Shukui
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma
Tabernero, J.
Bang, Y.
Van Cutsem, E.
Fuchs, C.
Janjigian, Y.
Bhagia, P.
Li, K.
Adelberg, D.
Qin, S.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S101 - S102
[25] A phase 3 study of chemotherapy 1 pembrolizumab vs chemotherapy 1 placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer: KEYNOTE-585-Trial in progress
Bang, Y.
Van Cutsem, E.
Fuchs, C.
Ohtsu, A.
Tabernero, J.
Ilson, D.
Hyung, W.
Strong, V.
Goetze, T.
Yoshikawa, T.
Tang, L.
Hwang, P.
Shitara, K.
[J]. ANNALS OF ONCOLOGY, 2018, 29
[26] 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1-Positive Advanced NSCLC
Herbst, R.
Garon, E.
Kim, D.
Cho, B. C.
Gervais, R.
Perez-Gracia, J. L.
Han, J.
Majem, M.
Forster, M. D.
Monnet, I.
Novello, S.
Gubens, M. A.
Boyer, M.
Su, W.
Samkari, A.
Jensen, E. H.
Piperdi, B.
Baas, P.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S223 - S224
[27] Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
Mok, T. S. K.
Lopes, G.
Cho, B. C.
Kowalski, D. M.
Kasahara, K.
Wu, Y. -l.
de Castro Jr, G.
Turna, H. Z.
Cristescu, R.
Aurora-Garg, D.
Loboda, A.
Lunceford, J.
Kobie, J.
Ayers, M.
Pietanza, M. C.
Piperdi, B.
Herbst, R. S.
[J]. ANNALS OF ONCOLOGY, 2023, 34 (04) : 377 - 388
[28] Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial
Brahmer, Julie R.
Rodriguez-Abreu, Delvys
Robinson, Andrew G.
Hui, Rina
Csoszi, Tibor
Fulop, Andrea
Gottfried, Maya
Peled, Nir
Tafreshi, Ali
Cuffe, Sinead
O'Brien, Mary
Rao, Suman
Hotta, Katsuyuki
Zhang, Jin
Lubiniecki, Gregory M.
Deitz, Anne C.
Rangwala, Reshma
Reck, Martin
[J]. LANCET ONCOLOGY, 2017, 18 (12): : 1600 - 1609
[29] Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Sugisaka, J.
Sugawara, S.
Toi, Y.
Ogasawara, T.
Aso, M.
Tsurumi, K.
Ono, K.
Shimizu, H.
Domeki, Y.
Aiba, T.
Kawana, S.
Saito, R.
Terayama, K.
Kawashima, Y.
Nakamura, A.
Yamanda, S.
Kimura, Y.
Honda, Y.
[J]. ANNALS OF ONCOLOGY, 2019, 30
[30] Phase 3 KEYNOTE-042 trial of pembrolizumab (MK-3475) versus platinum doublet chemotherapy in treatment-naive patients (pts) with PD-L1-positive advanced non-small cell lung cancer (NSCLC).
Mok, Tony
Wu, Yi-Long
Watson, Patricia A.
Zhang, Jin
Rangwala, Reshma A.
Lopes, Gilberto
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →